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Abstract
Background: Activating transcription factor 2 (ATF2) is a basic helix-loop-helix transcription factor, which has been
shown to participate in the pathobiology of numerous cancers. However, the role of ATF2 in renal cell carcinoma
(RCC) remains unclear.
Methods: ATF2 knockdown and overexpression studies were performed in RCC cells to evaluate changes in cell
viability, cell cycle, apoptosis, migration and invasion. Xenograft models were used to examine the tumorigenic and
metastatic capability of RCC cells upon ATF2 suppression. The expression of ATF2 in human RCC samples was determined
using immunohistochemistry on a tissue microarray.
Results: ATF2 knockdown in RCC cells reduced their proliferative and metastatic potentials, whereas ATF2 overexpression
enhanced these properties. Mechanistic studies revealed that the transcription of CyclinB1, CyclinD1, Snail and Vimentin
was directly regulated by ATF2 in RCC cells. Moreover, ATF2 was shown to be highly expressed in RCC tissues, especially
in tumors with metastases. High expression of ATF2 correlated with aggressive clinico-pathological characteristics and
predicted poor prognosis of RCC patients.
Conclusions: ATF2 exerts an oncogenic role in RCC and could serve as an important prognostic biomarker.
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Background
Renal cell carcinoma (RCC) is the most prevalent malig-
nancy of adult kidney, and its incidence has been increas-
ing in recent decades [1, 2]. Patients with early-stage
disease can be effectively treated with surgical resection,
however, approximately 20 % of patients present with
metastatic disease at the time of initial diagnosis. More-
over, up to 20 % of RCC patients will develop metastases
lesions following nephrectomy [3, 4]. Therefore, there is
an urgent need to elucidate the molecular mechanisms
underlying RCC progression, and identify novel bio-
markers and therapeutic targets to improve the prognosis
of RCC patients.
Activating transcription factor 2 (ATF2) is a member of
ATF family [5], characterized by a basic structural region
and a leucine zipper domain [6]. In response to extracellu-
lar stresses or inflammatory cytokines, the transcriptional
activity of ATF2 is induced through Thr69- and/or Thr71-
phosphorylation by Jun N-terminal kinase (JNK) or p38
(MAPK14) [7–9]. In melanoma and non-small cell lung
carcinoma, ATF2 acts as an important oncogene [10, 11],
while in nonmalignant skin and breast cancer, ATF2 elicits
tumor-suppressor function [12, 13], suggesting a context-
dependent role for ATF2 in cancer biology.
Currently, the role of ATF2 in the physiology and path-
ology of kidney is limited to the evidence that ATF2 has
been demonstrated to play a key role in the morphogenesis
and apoptosis of renal epithelial cells [14, 15], possibly
resulting in renal cyst formation [16]. However, the role of
ATF2 in RCC remains unknown. Herein, we examined the
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effects of ATF2 on the malignant phenotypes of RCC cells,
and explored its clinical significance in patients with RCC.
Methods
Cell lines and reagents
The human RCC cell lines ACHN and 786-O were
purchased from American Type Culture Collection
(ATCC, Rockville, MD, USA) and were cultured in MEM
(Invitrogen, Carlsbad, CA, USA) and RPMI-1640 (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) respect-
ively, and supplemented with 10 % fetal bovine serum
(Gibco, USA). Matrigel was purchased from BD (USA).
Patients and clinical samples
RCC patients who underwent surgery between January
2007 and April 2014 at the Department of Urology,
Changzheng Hospital, Second Military Medical University
(Shanghai, China) were enrolled in our study (n = 205).
The ethical approval was granted from the Committees
for Ethical Review at Second Military Medical University
and informed consent was obtained from all patients. All
specimens were formalin-fixed, paraffin embedded and
pathologically confirmed, and subsequently used to con-
struct a tissue microarray. The expression levels of ATF2
were examined by immunohistochemistry.
Immunohistochemistry (IHC)
Paraffin embedded sections were deparaffinized, rehy-
drated, and then prepared for antigen retrieval. Sections
were blocked with 10 % goat serum and incubated with
primary antibody against ATF2 (Proteintech-14834-1-
AP, dilution 1:50) at 4 °C overnight, and biotin-labeled
secondary antibody for 1 h at room temperature. Subse-
quently, the samples were developed by adding DAB and
counterstained with hematoxylin (Beyorime Institute of
Biotechnology, Inc.).
Plasmids and cell transfection
Human full-length cDNA of ATF2 was cloned into expres-
sion plasmid pCMV3-ATF2-Flag (Sino Biological lnc.). A
short hairpin RNA (shRNA) sequence was designed by
Hanbio Biotechnology Co. Ltd (Shanghai, China) to
target human ATF2 gene (NM_001256090.1). After an-
nealing, double strands of shRNA were inserted into
lentiviral pHBLV-U6-Puro vector (Addgene). For lentiviral
packaging, HEK-293 T cells were co-transfected with the
lentiviral vector, and packaging vectors psPAX2 and
PMD2G using LipoFiter™ Liposomal Transfection Reagent
(Hanbio, Shanghai, China), according to the manufacturer
instructions. RCC cells were seeded in 6-well plates and
grown to 50 % confluence on the day of infection. Four
hours prior to infection, cells were placed in serum-free
media and lentivirus particles were added to the culture
medium at a multiplicity of infection (MOI) of 30. Cells
were grown at 37 °C, and 24-h following transfection cells
were placed with fresh media. The sequences of primers
used for plasmid construction in this study were provided
in Additional file 1: Table S1.
Transfections were carried out using jetPRIME® -
Polyplus-transfection according to the manufacturer’s
protocol. One day prior to transfection, cells were seeded
in six-well plates. 4 μg of DNA was diluted into 150 mM
NaCl and 6 μl of jetPEI® was diluted into 150 mM NaCl to
a final volume of 200 μl per well. After 12 h, cells were
placed in fresh media.
RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cells and tissues using
TRIzol reagent (Invitrogen) according to the manufac-
turer instructions. First-strand cDNA was generated
from 2 μg total RNA using the PrimeScript RT reagent
kit (Takara, Dalian, China) with random primers. qRT-PCR
was performed on an ABI Prism 7300 (Applied Biosystems,
Foster City, CA, USA). Sequences of primers used for qRT-
PCR in this study were provided in Additional file 1:
Table S2. The relative expression level of indicated
genes was compared to that of β-Actin and was calcu-
lated using the 2−ΔΔCt method. Each qRT-PCR reaction
was performed in triplicate.
Western blot analysis
RCC cells were lysed using 1 × SDS sample buffer and
heated at 95 °C for 10 min. Quantified proteins were sepa-
rated on an SDS-PAGE and transferred to PVDF mem-
branes. The membranes were blocked with 5 % nonfat milk
for 2 h at room temperature and incubated with specific
antibodies. The following primary antibodies were used in
our study: ATF2 (Proteintech-14834-1-AP), Phospho-ATF2
(Thr71) (CST-9221), CyclinB1 (CST-12231), CyclinD1
(CST-2978), E-Cadherin (BS-1097), Snail (BS-1853),
Vimentin (BS-1491) and β-Actin (Santa cruz-81178).
Band intensity was quantitatively analyzed using Quantity
One software (Bio-Rad, USA), and the absolute intensity
of target protein was normalized to the absolute intensity
of β-Actin.
Cell proliferation assay
Cell proliferation was analyzed using the Cell Counting Kit
8 (CCK8, Beyotime Institute of Biotechnology, Shanghai,
China). RCC cells were seeded in 96-well plates at a
density of 2000 cells per well. At indicated time points,
10 μl CCK8 solution was added into each well and in-
cubated for 2 h. The absorbance at 450 nm was mea-
sured to assess the number of viable cells. The results
were obtained from three independent experiments in
triplicate.
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Plate colony formation assay
ACHN cells (500 cells) were seeded into 10 cm plates
and cultured in the 37 °C incubator for ~10 days until
most single colony were composed of more than 100
cells. The plates were washed by PBS, fixed with 4 %
paraformaldehyde, and stained with crystal violet. The
number of colonies containing more than 100 cells was
counted in each well.
Flow cytometry analysis
Cell apoptosis and cell cycle progression were quantified
using flow cytometry analysis (BD Biosciences, San Jose,
CA). For apoptosis experiment, RCC cells were collected
and washed twice with ice-cold PBS and re-suspended
in 200 μl binding buffer. FITC-conjugated Annexin V
was added to a final concentration of 0.5 μg/ml and
incubated for 20 min at room temperature in the dark,
prior to the addition of 1 μg/ml propidium iodide (PI).
Samples were immediately analyzed by flow cytometry.
For cell cycle progression, RCC cells were collected,
washed with PBS and fixed with 75 % ethanol. Cells
were stained with PI and RNase overnight at 4 °C. Sam-
ples were analyzed by flow cytometry.
Wound-healing assay
RCC cells were seeded at 5 × 105 cells/well in 6-well plates
and cultured until the plates were confluent. The cell
monolayer was scraped in a straight line using a 10 μl pip-
ette tip to create a scratch, washed with PBS twice and the
medium was replaced with serum free medium. Images
were captured at 0, 6, and12 h following the initial scratch
to evaluate cell migration.
Transwell assay
Cell transwell assays were performed with 24-well trans-
well chamber uncoated (migration) or matrigel-coated (in-
vasion) according to the manufacturer instructions (pore
size 8 μm, Corning Life Sciences, NY, USA). 1 × 104 serum
pre-starved RCC cells in 250 μl serum free media were
seeded into the upper chamber, and the bottom chamber
contained medium supplemented with 10 % FBS. After
24 h incubation, the cells on the upper surface of the
membrane were scraped off, and the cells on the bottom
Fig. 1 ATF2 is highly expressed in RCC samples. a qRT-PCR analysis of ATF2 in RCC cells versus human normal renal cells (293 T and HK-2).
b qRT-PCR analysis of ATF2 in RCC tissues and adjacent non-tumor tissues from 17 RCC patients. c Immunohistochemistry analysis of ATF2 in
RCC tissues (right) and adjacent non-tumor tissues (left). Scale bar = 50 μm. d Immunohistochemical comparison of ATF2 expression in human RCC
tissues versus adjacent non-tumor tissues. The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and
the whiskers represent the 2.5th and 97.5th percentiles. e qRT-PCR analysis of ATF2 in primary RCC tissues and tumor thrombus tissues from 9 patients.
Results are presented as mean ± SEM from three independent experiments. *p < 0.05 and **p <0.01
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side of the membrane were fixed with 4 % paraformal-
dehyde and stained with crystal violet. Cells were
counted from 8 randomly chosen fields (magnification,
×200).
Chromatin immunoprecipitation (ChIP)
Following transfection, 786-O cells (1 × 107 cells) were
cross-linked with 1 % formaldehyde and incubated for
10 min at 37 °C. ChIP assay was performed according to
the manufacturer’s protocol (Millipore, USA) using mono-
clonal Anti-Flag® M2 antibody produced in mouse (Sigma)
or normal rabbit IgG as a negative control (Santa Cruz
Biotechnology). An aliquot of lysates (20 μl) was taken out
as input control. DNA enrichment was determined by
quantitative PCR (qPCR), and was normalized to input.
Sequences of primers used for ChIP-qPCR in this study
were provided in Additional file 1: Table S3. The products
of qPCR were detected by agarose gel electrophoresis.
In vivo tumor xenograft experiment
Male nude mice (BALB/c Nude; 4 weeks old) were pur-
chased from the Shanghai Institute of Material Medical
(Chinese Academy of Science) and maintained in a
pathogen-free condition in accordance with relevant guide-
lines and regulations for the care and use of laboratory ani-
mals, with the approval of the Institutional Animal Care
and Use Committee at Second Military Medical University.
ACHN cells (5 × 106 cells) in 100 μl PBS were implanted
subcutaneously into the flanks of nude mice. Tumor size
was monitored at 3 days intervals using calipers, and the
tumor volumes were calculated according to the follow-
ing formula: tumor volume = largest diameter × perpen-
dicular height2 × 0.5. For lung metastasis model, ACHN
cells (1 × 106 cells) in 200 μl PBS were injected into the
tail vein of mice. Mice were sacrificed 12 weeks after
inoculation and consecutive sections of the whole lung
were subjected to hematoxylin-eosin staining. All of the
metastatic lesions in lung were calculated microscopically
to evaluate the development of pulmonary metastasis.
TUNEL assay
Apoptosis in tumor tissues was detected by DNA frag-
mentation with an apoptosis detection kit (Roche
TUNEL-Apo-AP; USA) according to the manufacturer
instruction. Tissues were deparaffinized and hydrated
as previously described. The samples were developed
by adding DAB and counterstained with hematoxylin
(Beyorime Institute of Biotechnology, Inc.). Images were
taken with a Nikon microscope at 200× magnifications.
Statistical analysis
Statistical analysis was performed with SPSS Statistics
software version 19 (SPSS Inc., USA). Data were presented
as “mean ± SD”. Pearson chi-square test was used to
analyze the clinical variables. Kaplan-Meier method and
log-rank tests were used to compare RCC patient survival
based on dichotomized ATF2 expression. Cox propor-
tional hazards regression analysis were used to analyze the
independent factors on the survival prognosis of patients
with RCC. Differences between groups were analyzed
by Student’s t-test after evaluating the normal distribu-
tion of results. A p-value < 0.05 was considered statisti-
cally significant.
Results
ATF2 is highly expressed in RCC tissues
The expression of ATF2 was detected in various RCC
cell lines. As shown in Fig. 1a, the upregulation of ATF2
was observed in RCC cell lines compared to normal kid-
ney cell lines. The average mRNA expression of ATF2
was higher in RCC tumors than that in corresponding
adjacent normal tissues (Fig. 1b). Immunostaining ana-
lysis on tissues microarray further confirmed that ATF2
was increased in RCC tissues and showed predominant
expression in nucleus compared with adjacent normal
(See figure on previous page.)
Fig. 2 ATF2 promotes RCC cells proliferation in vitro. a CCK8 assay of ATF2 knockdown and control RCC cells at indicated times. b Plate colony
formation assay of ATF2 knockdown and control ACHN cells in 10 cm dish for 3 weeks (n = 3). Average number of colonies (upper) and representative
images (lower) were shown. c Flow cytometry analysis of cell cycle in ATF2 knockdown and control RCC cells. Representative cell cycle distributions
were shown (left) and the histogram columns represent the average percentages of G0/G1, S and G2/M phases (right). d Flow cytometry analysis of
apoptotic cells in ATF2 knockdown and control RCC cells (left) and the percentage of cells at the different apoptosis phases (right). The bar charts
showed the increases in the early and late apoptotic indexes of RCC cells transfected with shATF2. e CCK8 assay of ATF2 overexpression and control
RCC cells at indicated times. f Plate colony formation assay of ATF2 overexpression and control ACHN cells in 10 cm dish for 3 weeks (n = 3). Average
number of colonies (upper) and representative images (lower) were shown. g Flow cytometry analysis of cell cycle in ATF2 overexpression and control
RCC cells. Representative cell cycle distributions were shown (left) and the histogram columns represent the average percentages of G0/G1, S and G2/
M phases (right). h & i Western blotting analysis of Cyclin B1 and Cyclin D1 in ATF2 knockdown (h), ATF2 overexpression (i) and control ACHN cells.
β-Actin was used as an internal standard. j ChIP assay analysis of the enrichment of ATF2 at the proximal promoter region of Cyclin B1 and Cyclin D1 in
the context of ATF2 overexpression. The enrichment of ATF2 (upper) on Cyclin B1 or Cyclin D1 promoter relative to input in 786-O cells
and gel electrophoresis of PCR products from ChIP assay (lower). Results are presented as mean ± SEM from three independent experiments. *p < 0.05,
**p <0.01 and *** p < 0.001
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tissues (Fig. 1c and Fig. 1d). Notably, ATF2 expression
was even higher in tumor thrombus than primary tu-
mors (Fig. 1e). Together, these results prompted an
oncogenic role of ATF2 in RCC progression.
ATF2 promotes RCC cells proliferation by promoting
Cyclin expression
To investigate the biological function of ATF2 in RCC
cells, lentivirus-based short hairpin RNAs (shRNAs) was
used to suppress ATF2 expression. ATF2 shRNA substan-
tially decreased ATF2 mRNA and protein levels compared
to control groups (Additional file 1: Figure S1A and 1B).
CCK8 assay and plate colony formation assay were per-
formed to characterize the role of ATF2 in cell prolifera-
tion. As shown in Fig. 2a, ATF2 knockdown resulted in
reduced proliferation of RCC cells. The size and number
of single colony was also decreased in ATF2 knockdown
ACHN cells (Fig. 2b).
We then evaluated the cell cycle distribution by flow cy-
tometry. Knockdown of ATF2 increased the proportion of
cells in G0/G1 phase, with concomitant decrease in S and
G2/M phase (Fig. 2c). These results indicated that ATF2
may promote cell cycle progression. In addition, suppres-
sion of ATF2 enhanced the ratio of early and late apop-
totic cells (Fig. 2d).
Conversely, exogenous expression of ATF2 in RCC
cells (Additional file 1: Figure S1C and 1D) enhanced
cell proliferation and induced an increase in the number
of cells in S phase compared to control cells (Fig. 2e-2g).
Cell cycle is precisely regulated by cyclins, we there-
fore evaluated the effect of ATF2 on their expressions.
Notably, the mRNA and protein expression of CyclinB1
and CyclinD1 were downregulated upon ATF2 knock-
down (Additional file 1: Figure S2A and Fig. 2h) and up-
regulated upon ATF2 overexpression (Additional file 1:
Figure S2B and Fig. 2i). Moreover, ChIP assay demon-
strated that ATF2 was enriched on the proximal pro-
moters of CyclinB1 and CyclinD1 in cells overexpressing
ATF2 (Fig. 2j), indicating that ATF2 bound to the pro-
moter of CyclinB1 and CyclinD1 and promoted their
transcription. Taken together, these results revealed
that ATF2 promotes RCC cells proliferation at least in
part by transactivating the expression of CyclinB1 and
CyclinD1.
ATF2 facilitates RCC cell migration and invasion
RCC is prone to metastasis to distant organs [17]. We
next explored the role of ATF2 in cell migration and in-
vasion. Wound-healing assay and transwell assay re-
vealed that ATF2 knockdown significantly inhibited cell
migration (Fig. 3a and 3b), while ATF2 overexpression
enhanced the migratory abilities of RCC cells (Fig. 3c).
Matrigel invasion chamber assay demonstrated that
ATF2 knockdown suppressed cell invasion in RCC cells
(Fig. 3d) and ATF2 overexpression led to enhanced inva-
sion (Fig. 3e).
Epithelial to mesenchymal transition (EMT) plays a piv-
otal role in tumor metastasis [18, 19]. We thus examined
the effect of ATF2 on the expression of EMT markers.
Increased levels of epithelial markers (E-Cadherin) and de-
creased levels of mesenchymal markers (Snail and Vimen-
tin) were detected in RCC cells following ATF2 knockdown
(Additional file 1: Figure S2C and Fig. 3f). Conversely,
ATF2 overexpression decreased E-Cadherin expression and
increased the expression of Snail and Vimentin (Additional
file 1: Figure S2D and Fig. 3g). Furthermore, we observed
an enrichment of ATF2 at the proximal promoter region of
Snail and Vimentin upon ATF2 overexpression (Fig. 3h).
Thus, these results suggest that ATF2 promotes RCC me-
tastasis partially depending on EMT induction.
ATF2 knockdown suppresses tumor growth and
metastasis in vivo
To further explore the role of ATF2 in RCC growth in
vivo, ATF2 knockdown or control ACHN cells were
injected subcutaneously into nude mice. As shown in
Fig. 4a-4c, tumor volume and weight were reduced in
ATF2 shRNA group compared to control group. Immuno-
staining showed the proliferation marker Ki-67 was weaker
in ATF2 knockdown tumors (Fig. 4d). And TUNEL assay
demonstrated that apoptotic cells were increased in
tumors from ATF2 shRNA group (Fig. 4e). In addition, the
(See figure on previous page.)
Fig. 3 ATF2 facilitates RCC cell migration and invasion in vitro. a Left: representative images of the wound-healing assay of ATF2 knockdown and
control RCC cells photographed at 0, 6 and 12 h after scratching. Scale bar = 200 μm. Right: the relative migration rate was calculated by dividing
the change in the distance between the scratch edges by the initial distance. b & c Transwell assays were performed to evaluate cell migration
following ATF2 knockdown (b), ATF2 overexpression (c) and control RCC cells. The statistical graph indicates the means ± SEM of the number of
cells from 8 random high power fields (magnification, ×200) counted from three independent experiments. Scale bar = 2 mm. d & e Transwell
assays were performed to evaluate the invasion of ATF2 knockdown (d), ATF2 overexpression (e) and control RCC cells. The statistical graph
indicates the means ± SEM of the number of cells from 8 random high power fields (magnification, ×200) counted from three independent
experiments. Scale bar = 2 mm. f & g Western blotting analysis of Snail, Vimentin and E-Cadherin in ATF2 knockdown (f), ATF2 overexpression (g)
and control 786-O cells. β-Actin was used as an internal standard. h ChIP assay analysis of the enrichment of ATF2 at the proximal promoter
region of Snail and Vimentin in the context of ATF2 overexpression. The enrichment of ATF2 on Snail and Vimentin promoter relative to input in
786-O cells (upper). The gel electrophoresis of PCR products from ChIP assay (lower). Results are presented as mean ± SEM from three independent
experiments. *p < 0.05, **p <0.01, and ***p < 0.001
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Fig. 4 ATF2 knockdown suppresses tumor growth in vivo. a A representative nude mice showing the morphology of the tumors derived from
ATF2 knockdown and control ACHN cells (upper). The tumors were dissected and photographed (lower). b The growth curve of the ATF2
knockdown versus the control ACHN tumors. c The average weight of ATF2 knockdown versus the control ACHN tumors. d Ki-67 staining of
ATF2 knockdown versus the control ACHN tumors. Scale bar = 50 μm. e TUNEL assay analysis of the cell apoptosis in ATF2 knockdown versus the
control ACHN tumors (left). Apoptosis cells numbers per view were shown (right). Scale bar = 50 μm. f qRT-PCR analysis of ATF2, Cyclin B1 and
Cyclin D1 in ATF2 knockdown versus the control ACHN tumors. g Left: representative images of HE staining of metastatic nodules in the lungs of
nude mice. The metastatic nodules are indicated by yellow arrows. Scale bar = 100 μm. Right: the numbers of nude mice with metastatic nodules
in the lungs were calculated and compared (p = 0.016). Results are presented as means ± SEM for each group (n = 6). *p < 0.05, **p <0.01,
and ***p < 0.001
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mRNA levels of CyclinB1 and CyclinD1 were decreased in
the ATF2 knockdown tumors (Fig. 4f). These data demon-
strate that the inhibition of ATF2 suppressed the tumori-
genicity of RCC cells in vivo.
To examine the effect of ATF2 on RCC metastasis in vivo,
we established a lung metastasis model. As shown in Fig. 4g,
RCC cells with ATF2 knockdown formed decreased num-
ber and size of pulmonary metastatic lesions in mice.
High levels of ATF2 predict poor prognosis of RCC
patients
To evaluate the clinical significance of ATF2 in RCC
patients, we analyzed the correlation between ATF2
expression and the clinical characteristics of patients.
As shown in Fig. 5a-5c, ATF2 was elevated in RCC tis-
sues with larger tumor size, tumor thrombus or dis-
tant metastasis. According to the median expression
of ATF2, 205 RCC patients were divided into two
groups: high-ATF2 (n = 102) and low-ATF2 (n = 103).
High ATF2 expression was associated with larger
tumor size (p = 0.007), advanced pathological stage (p =
0.024), tumor thrombus (p = 0.032) and distant metastasis
(p = 0.022) (Additional file 1: Table S4). Furthermore, pa-
tients in the high ATF2 group exhibited a worse overall
survival (OS) and disease-free survival (DFS) than those in
low ATF2 group (Fig. 5d and 5e). Multivariate analysis
identified high ATF2 level in RCC tissues as an independ-
ent prognostic factor for RCC patients (Additional file 1:
Tables S5 and S6).
Discussion
Emerging evidence has indicated that ATF2 exerts para-
doxical roles in different cancers [20]. For instance, ATF2
acts as a tumor suppressor in breast cancer by promoting
the expression of the apoptosis-regulated gene GADD45α
and suppressor gene Maspin [21]. Similarly, the deletion
of ATF2 in keratinocytes upregulated of β-catenin and
downregulated of Notch consequently facilitated skin
tumor formation [13]. By contrast, inhibition of ATF2 re-
pressed tumorigenesis of melanoma via increasing JNK/
Jun and JunD activities [22]. Therefore, the role of ATF2
may depend on cancer-specific contexts and its role in
RCC remains unknown. In this study, we reported the
oncogenic role of ATF2 in the regulation of RCC growth
and metastasis both in vitro and in vivo. By using a large
Fig. 5 High levels of ATF2 predicts poor prognosis of RCC patients. a & b & c Comparison of ATF2 expression in human RCC tissues with
diameter > 4 cm or ≤ 4 cm (a), RCC tissues with or without tumor thrombus (b), RCC tissues with or without tumor metastasis (c) determined by
immunohistochemistry. The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and the whiskers
represent the 2.5th and 97.5th percentiles. d Patients in comparative ATF2 high group (n = 102) had lower overall survival time than those in
comparative ATF2 low group (n = 103) (P = 0.017). e Patients in comparative ATF2 high group (n = 102) had lower disease-free survival time than
those in comparative ATF2 low group (n = 103) (P = 0.031)
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cohort of RCC patients, we identified ATF2 as a novel bio-
marker to predict RCC prognosis.
Cell proliferation needs cell cycle progression, which is
known to be controlled by cyclins. Cyclin B1 and Cyclin
D1 are key regulators for G1/S and G2/M transition
respectively [23–26], depletion of which inhibited prolifer-
ation and induced apoptosis in many human tumors [23].
ATF2 has been reported to modify Cyclin B1 and Cyclin
D1 levels to promote cell-cycle progression in several
types of neoplasms, including cervical and breast cancer
[27, 28]. Our results further revealed the enrichment of
ATF2 at the proximal promoter region of Cyclin B1 and
Cyclin D1, suggesting that ATF2 promotes the transcrip-
tion of Cyclin B1 and Cyclin D1 to enhance RCC cell
proliferation.
EMT plays a pivotal role in tumor metastasis and
contributes to early-stage dissemination of cancer cells
[29–31]. ATF2 was reported to promote metastasis by
regulating EMT in solid tumors such as pancreatic cancer
[32]. However, this relationship has never been demon-
strated in RCC. Herein, we found that depletion of ATF2
caused a conversion from mesenchymal to epithelial
phenotype, marked by upregulation of E-cadherin and
downregulation of Snail and Vimentin. Furthermore, we
found that Snail and Vimentin were direct downstream
targets of ATF2 in RCC cells, suggesting that ATF2 en-
hanced metastasis of RCC cells by the induction of EMT.
As a transcription factor, the divergent roles of ATF2
may be associated with differential subcellular localization
[33]. In the present study, we found that ATF2 expression
was higher in RCC samples and primarily localized in the
nucleus of RCC cells (Fig. 1c), suggesting the transcrip-
tional function of ATF2. Consistent with the oncogenic
role of ATF2 in functional study, RCC patients with high
ATF2 expression were associated with aggressive clinico-
pathological characteristics. Moreover, high ATF2 level
was significantly correlated with decreased survival in
RCC patients, and could serve as an independent pre-
dictor for poor prognosis.
Conclusions
In summary, ATF2 plays a critical role in promoting cell
proliferation and metastasis of RCC, and could serve as an
independent predictor for the clinical outcome in RCC
patients. Based on these findings, targeting ATF2 may rep-
resent a potential therapeutic strategy to curb the progres-
sion of RCC.
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